Skip to content
Tech News
← Back to articles

Anthropic is operating a lab that conducts biology experiments

read original more articles
Why This Matters

Anthropic's confirmation that it runs a physical wet lab shows AI companies are moving beyond software into hands-on scientific experimentation, signaling a deeper push into biotech that could accelerate drug discovery while raising new safety and competitive concerns. This move also highlights tensions between AI firms' ambitions and their partnerships with pharma customers, as well as ongoing internal debates about AI risk.

Key Takeaways

Anthropic has has a wet biology lab in the Bay Area where it can use its AI models to run physical experiments, it has confirmed to TechCrunch.

AI leaders have been promising that AI is the key to curing human disease. Dario Amodei opined just last week: “I believe that AI could cure most major diseases in the next 5–10 years.” To do that, an LLM would have to have methods to test its theories in real life.

“We believe that to do biology, the final test is still, and will be for a while, in real lab work,” Anthropic’s head of life sciences, Eric Kauderer-Abrams told Reuters. “We absolutely are doing that today.” He added that the lab operates like most biotech labs: Anthropic conducts some research there while also working with externals partners.

This news probably shouldn’t be shocking. Anthropic bought Coefficient Bio, a stealth AI biotech, in April.

While Anthropic, declined to give specifics on what the wet lab is working on, it did say the main focus was fundamental biology, not drug discovery.

Anthropic doesn’t want to give the appearance of competing with the pharma industry, where it has numerous major customers and partners. (For instance, it just announced a deal to work with Novo Nordisk on joint drug discovery.) Anthropic has already faced backlash for launching products perceived to compete with those of its customers.

To that end, Anthropic also launched a Life Sciences Verification Program this week, to give vetted bio researchers access to its most powerful models. It has also published recent reports on some of the research it’s doing to support drug discovery. This includes a report on accelerating protein design and one on uplifting bimolecular modeling.

But the world is still reeling from the resignation of Anthropic researcher Jacob Coxon, who warned that “the people building AI earnestly believe that it could kill us all by the end of the decade.” Anthropic’s own alignment lead gave the odds at greater than 10% that AI could exterminate humanity within the next decade.

The fervor has grown so intense that CEO Dario Amodei published a post last weekend calling on the industry to slow down and institute self-regulation. He has repeatedly called bioterrorism one of AI’s biggest risks.

The juxtaposition of these dire warnings and the wet lab has not gone unnoticed in the tech industry. As investor and AI coding startup founder Chamath Palihapitiya posted on X, somewhat tongue-in-cheek: “The group behind such hits as: “We’re All Going To Die” and “Regulate Me Now” are building a wet lab in SF. I do not recommend this.”